ABSTRACT
Psoriatic arthritis (PsA), which affects musculoskeletal structures, skin and nails, is a chronic inflammatory disease. The treatment of PsA has changed tremendously over the past decade owing to the improvement in early diagnosis and treatment strategies. TNF-α blockers, including adalimumab, etanercept, golimumab and infliximab, are representatives of a revolution in the treatment of PsA. Certolizumab (a new anti-TNF agent) and ustekinumab (a fully human monoclonal antibody against IL-12 and IL-23) are approved for the treatment of active PsA. In recent years, multiple small molecule drugs targeting Janus kinase/signal transducers and activators of transcription signaling pathway have been developed and applied to treat PsA in clinic. Developing better targeted drugs is an important research direction for the treatment of psA in the future.